Document is current
Any future updates will be listed below
-
Authors
Cox, Kristin E.
Amirfakhri, Siamak
Lwin, Thinzar M.
Hosseini, Mojgan
Ghosh, Pradipta
Obonyo, Marygorret
Hoffman, Robert M.
Yazaki, Paul J.
Bouvet, Michael https://orcid.org/0000-0002-0086-2159
-
Funding
Funding for this research was provided by:
Padres Pedal the Cause Collaborative Translational Pilot Project (PCT2022, PTC2021)
U.S. Department of Veterans Affairs (1 I01 BX003856-01A1, 1 I01 BX004494-01)
National Cancer Institute Cancer Center Support Grant (P30CA23100)
National Institutes of Health (CA100768, CA121938, CA238042, CA256973-01)
U.S. Department of Defense (W81XWH-20-1-0675)
Curebound Foundation (20DG03)
- License Information
-
More Information
Article History
Received: 28 June 2024
Accepted: 7 January 2025
First Online: 29 January 2025
Disclosure
: RMH is a nonsalaried affiliate of AntiCancer, Inc. producing patient-derived orthotopic xenograft mouse models for contract research. PY declares a patent covering the anti-CEA M5A antibody for fluorescence guided surgery.
